Skip to main content

Testing version — LOERadar is in active testing. Features and data may change.

Hub News Changes Search

LOERadar

FDA drug patent and exclusivity intelligence, assembled from public records.

Sponsored by

About Terms of Service Privacy Policy Log in

Attorney Advertising

© 2026 LOERadar · An informational research tool drawn from public records; it is not a law firm, does not provide legal advice, and its use does not create an attorney-client relationship.

IMIPENEM AND CILASTATIN (CILASTATIN SODIUM; IMIPENEM) | LOERadar

Viewing data from:

IMIPENEM AND CILASTATIN

ANDA

CILASTATIN SODIUM; IMIPENEM | A207594 | HQ SPECIALTY PHARMA CORP

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: PRIMAXIN(TE code: AP)

Products (1)

#001 — EQ 500MG BASE/VIAL;500MG/VIAL

AP

0 patents0 exclusivities▴

POWDER;INTRAVENOUS | Approved: Dec 12, 2019

No patent or exclusivity listings for this strength.